← All articles

Infant Deaths, Hospitalizations Linked to Cereulide-Contaminated Formula

Three infant deaths in France are under investigation for links to recalled formula, and multiple hospitalizations were recorded in Belgium. The contaminating agent, cereulide, lacked EU regulatory limits at the time of the crisis, and France had no domestic lab capacity to detect it. EFSA has since set maximum reference doses for the toxin.

AI-assisted reporting

The essentials

Cereulide-contaminated infant formula is linked to three infant deaths in France and hospitalizations in Belgium.

Three infant deaths in France are under investigation for a potential link to recalled infant formula, with two cases remaining unresolved. In Belgium, consumption of contaminated formula has been connected to multiple infant hospitalizations.

The contamination involves cereulide, a toxin for which the European Food Safety Authority (EFSA) has since established maximum reference doses in infant formula powder. However, France lacked the domestic laboratory capacity to detect cereulide at the required detection thresholds during the crisis, raising questions about preparedness.

Nestlé conducted an initial recall in December 2025 without a public announcement, citing the absence of EU-level cereulide regulations at the time as justification for the limited disclosure.

Broaden the view

Other ways to read this story.

Alternative framings generated by SigNews. These are not independent sources or attributed quotations.

Public Health

Detection Gaps Left Infants Exposed to Unregulated Toxin

France's inability to detect cereulide at required thresholds during the crisis points to a structural gap in food safety infrastructure. With no EU regulatory limits for cereulide in place at the time, and no domestic testing capacity, the health system had limited tools to identify or respond to the contamination before infants were harmed.

Industry

Nestlé's Silent Recall Draws Scrutiny Amid Regulatory Vacuum

Nestlé's decision to recall formula in December 2025 without a public announcement, justified by the absence of EU cereulide regulations, raises questions about corporate disclosure standards when formal rules are absent. The episode highlights a tension between regulatory compliance and proactive public communication during potential health emergencies.